AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 54(3), 1996, pp. 237-242
Copyright © 1996 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Hensbroek, M. B.
Right arrow Articles by Kager, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Hensbroek, M. B.
Right arrow Articles by Kager, P. A.

Quinine Pharmacokinetics in Young Children with Severe Malaria

Michael Boele Van Hensbroek, Dominic Kwiatkowski, Bob Van den Berg, Frans J. Hoek, Chris J. Van Boxtel AND Piet A. Kager
Medical Research Council, Fajara, The Gambia; Department of Infectious Diseases and Tropical Medicine, Department of Clinical Pharmacology, and Special Laboratory of Medicine and Surgery, Academical Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Paediatrics, John Radcliffe Hospital, Oxford, United Kingdom

Children less than two years of age represent a substantial proportion of severe malaria cases in Africa. The standard treatment is parenteral quinine, but little is known about the pharmacokinetics and toxicity of quinine in this age group. We have studied the pharmacokinetics of quinine after intravenous (iv) and intramuscular (im) administration in a group of 20 children less than two years of age with severe malaria. A loading dose of 20 mg/kg of quinine dihydrochloride was followed by 10 mg/kg at 12-hr intervals. The im quinine was very rapidly absorbed, reaching high peak concentrations of 16.4 ± 3.7 mg/L (mean ± SD) in 1.1 ± 0.4 hr. Mean peak levels after iv administration were also high (17.5 ± 2.4 mg/L). Free quinine levels at 4 hr postadministration ranged from 0.27 to 1.89 mg/L (0.87 ± 0.53 mg/L). At 2 hr and 4 hr after commencing treatment, an electrocardiogram showed a significant lengthening of the QRS interval compared with baseline (15.6 ± 21.4%; P = 0.007 and 17.3 ± 21.9%; P = 0.006 at 2 hr and 4 hr, respectively), whereas this was not observed in a control group of nine older children (age range = 24 months to 10 years) receiving the same im dosage regimen. Free and total quinine levels were not significantly correlated with changes in the QRS interval. Levels of {alpha}1-acid glycoprotein, which binds quinine within the circulation, did not differ between the younger and the older children. These findings raise the possibility that young children are more susceptible to quinine toxicity than older children, and indicate the need for further evaluation of quinine dosage regimens in this age group.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Society of Tropical Medicine and Hygiene.